Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson's Disease
Interventions
ExAblate Transcranial System
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Parkinson Disease, Idiopathic, Parkinson Disease
Interventions
Deep brain stimulation
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Parkinson Disease
Interventions
Spectramax light therapy device, Control light device
Device
Lead sponsor
PhotoPharmics, Inc.
Industry
Eligibility
45 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Orem, Utah
Conditions
Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Fort Wayne, Indiana + 6 more
Conditions
Idiopathic Parkinson Disease
Interventions
XADAGO (safinamide)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Homewood, Alabama • Bakersfield, California • Laguna Hills, California + 27 more
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Observational cohort
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
Conditions
Parkinson Disease
Interventions
ExAblate Pallidotomy, Sham ExAblate Pallidotomy
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Stanford, California • Boynton Beach, Florida • Baltimore, Maryland + 7 more
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Idiopathic Parkinson Disease
Interventions
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors, Saline
Biological · Other
Lead sponsor
The Neurology Center
Other
Eligibility
45 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Idiopathic Parkinson Disease
Interventions
VTX3232
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Idiopathic Parkinson's Disease
Interventions
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]), Sham Surgery
Drug · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 6 more
Completed Not applicable Interventional Results available

Voice Treatment for Parkinson's Disease

NCT03700684
Conditions
Idiopathic Parkinson Disease
Interventions
Lee Silverman Voice Treatment, SpeechVive, Control
Behavioral · Device
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
West Lafayette, Indiana • Amherst, Massachusetts
Conditions
Parkinson's Disease With Cognitive Impairments
Interventions
safinamide, placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
45 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
9
States / cities
Sunnyvale, California • Jacksonville, Florida • Atlanta, Georgia + 5 more
Conditions
Parkinson's Disease
Interventions
TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
301 participants
Timeline
2002 – 2003
U.S. locations
11
States / cities
Phoenix, Arizona • Berkley, California • Fountain Valley, California + 8 more
Conditions
Tremor Associated With Tremor Dominant Parkinson's Disease
Interventions
Unilateral thalamotomy
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 4 more
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
[F-18] Fluorodopa Positron Emission Tomography, OM Meditation
Drug · Behavioral
Lead sponsor
Andrew Newberg
Other
Eligibility
25 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Conditions
Parkinson Disease
Interventions
NeuraLight
Other
Lead sponsor
NeuraLight
Industry
Eligibility
40 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinimide 50-100 mg/day, Matching Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Conditions
Idiopathic Parkinson's Disease (PD)
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more